ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för afamelanotide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2020-08-18

Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.

Barman-Aksözen J, Nydegger M, Schneider-Yin X, Minder AE.

Orphanet J Rare Dis · research support, non-u.s. gov't; research-article; journal article; observational study · DOI 10.1186/s13023-020-01505-6

Bibliografisk träff 2020-05-01

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.

Wensink D, Wagenmakers MAEM, Barman-Aksözen J, Friesema ECH, Wilson JHP, van Rosmalen J, Langendonk JG.

JAMA Dermatol · brief-report; journal article · DOI 10.1001/jamadermatol.2020.0352

Bibliografisk träff 2020-04-01

[Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide].

de Baat C, Phoa KH, Zweers PGMA, Bolling MC, Rozema FR, Vissink A.

Ned Tijdschr Tandheelkd · journal article · DOI 10.5177/ntvt.2020.04.19115

Bibliografisk träff 2020-01-25

Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.

Toh JJH, Chuah SY, Jhingan A, Chong WS, Thng STG.

J Am Acad Dermatol · letter; randomized controlled trial · DOI 10.1016/j.jaad.2020.01.035

Bibliografisk träff 2019-10-28

NDP-MSH binding melanocortin-1 receptor ameliorates neuroinflammation and BBB disruption through CREB/Nr4a1/NF-κB pathway after intracerebral hemorrhage in mice.

Wu X, Fu S, Liu Y, Luo H, Li F, Wang Y, Gao M, Cheng Y, Xie Z.

J Neuroinflammation · research-article; journal article · DOI 10.1186/s12974-019-1591-4

Bibliografisk träff 2018-11-01

Afamelanotide in the Treatment of Dermatologic Disease

McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH.

Skin Therapy Lett · journal article

Bibliografisk träff 2017-08-01

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Minder EI, Barman-Aksoezen J, Schneider-Yin X.

Clin Pharmacokinet · research support, non-u.s. gov't; review; journal article · DOI 10.1007/s40262-016-0501-5

Bibliografisk träff 2016-12-12

Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

Lane AM, McKay JT, Bonkovsky HL.

Appl Clin Genet · review-article; review; journal article · DOI 10.2147/tacg.s122030

Bibliografisk träff 2016-04-01

Afamelanotide: A Review in Erythropoietic Protoporphyria.

Kim ES, Garnock-Jones KP.

Am J Clin Dermatol · review; journal article · DOI 10.1007/s40257-016-0184-6

Bibliografisk träff 2015-07-01

Afamelanotide for Erythropoietic Protoporphyria.

Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ.

N Engl J Med · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa1411481

Bibliografisk träff 2015-04-30

Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.

Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI.

Br J Dermatol · multicenter study; journal article; observational study · DOI 10.1111/bjd.13598

Bibliografisk träff 2015-03-01

Indications and limitations of afamelanotide for treating vitiligo.

Passeron T.

JAMA Dermatol · comment; journal article · DOI 10.1001/jamadermatol.2014.4848

Bibliografisk träff 2015-03-01

Indications and limitations of afamelanotide for treating vitiligo-reply.

Lim HW, Grimes PE, Lebwohl M.

JAMA Dermatol · comment; journal article · DOI 10.1001/jamadermatol.2014.4951

Bibliografisk träff 2015-01-01

Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.

Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M.

JAMA Dermatol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1001/jamadermatol.2014.1875

Bibliografisk träff 2014-12-03

Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.

Minder EI, Schneider-Yin X.

Expert Rev Clin Pharmacol · research support, non-u.s. gov't; review; journal article · DOI 10.1586/17512433.2014.956089

Bibliografisk träff 2014-11-13

Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.

Lengweiler S, Kreim S, Barman-Aksözen J, Maurer M, Minder EI.

Skin Pharmacol Physiol · clinical trial, phase iii; clinical trial, phase ii; journal article · DOI 10.1159/000362174

Bibliografisk träff 2013-07-01

A review and update on melanocyte stimulating hormone therapy: afamelanotide.

Fabrikant J, Touloei K, Brown SM.

J Drugs Dermatol · review; journal article

Bibliografisk träff 2013-01-01

The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.

Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW.

JAMA Dermatol · research support, non-u.s. gov't; journal article; case reports · DOI 10.1001/2013.jamadermatol.386

Bibliografisk träff 2012-12-05

A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.

Spichty R, Balimann M, Barman J, Minder EI.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2012.11.040

Bibliografisk träff 2011-09-01

Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis.

von Bartenwerffer W, Siebenhaar G, Hunzelmann N.

Acta Derm Venereol · letter; case reports · DOI 10.2340/00015555-1062

Bibliografisk träff 2010-11-13

Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.

Minder EI.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2010.535515

Bibliografisk träff 2009-01-01

An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria.

Harms J, Lautenschlager S, Minder CE, Minder EI.

N Engl J Med · letter; research support, non-u.s. gov't · DOI 10.1056/nejmc0805682

Bibliografisk träff 2006-03-24

Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils.

Giuliani D, Leone S, Mioni C, Bazzani C, Zaffe D, Botticelli AR, Altavilla D, Galantucci M, Minutoli L, Bitto A, Squadrito F, Guarini S.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2006.03.038

Bibliografisk träff 2005-11-15

Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.

Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM.

Peptides · randomized controlled trial; journal article · DOI 10.1016/j.peptides.2004.12.038